DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents

Abstract

A class of diagnostic and therapeutic compounds derived from phosphinimines that include ligands containing either a single phosphinimine functionality or both a phosphinimine group and a phosphine or arsine group, or an aminato group, or a second phosphinimine moiety. These phosphinimine ligands are complexed to early transition metal radionuclides (e.g. .sup.99m Tc or .sup.186 Re/.sup.188 Re) or late transition metals (e.g., .sup.105 Rh or .sup.109 Pd). The complexes with these metals .sup.186 Re/.sup.188 Re, .sup.99m Tc and .sup.109 Pd exhibit a high in vitro and high in vivo stability. The complexes are formed in high yields and can be neutral or charged. These ligands can also be used to form stable compounds with paramagnetic transition metals (e.g. Fe and Mn) for potential use as MRI contrast agents. Applications for the use of ligands and making the ligands are also disclosed.

Inventors:
 [1];  [1];  [1];  [1]
  1. Columbia, MO
Issue Date:
Research Org.:
Univ. of Missouri, Columbia, MO (United States)
OSTI Identifier:
870821
Patent Number(s):
5601800
Assignee:
Curators of University of Missouri (Columbia, MO)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07B - GENERAL METHODS OF ORGANIC CHEMISTRY
DOE Contract Number:  
FG02-89ER60875
Resource Type:
Patent
Country of Publication:
United States
Language:
English
Subject:
multifunctional; ligands; potential; design; therapeutic; diagnostic; radiopharmaceutical; imaging; agents; compounds; derived; phosphinimines; containing; single; phosphinimine; functionality; phosphine; arsine; aminato; moiety; complexed; transition; metal; radionuclides; 99m; tc; 186; 188; metals; 105; 109; pd; complexes; exhibit; vitro; vivo; stability; formed; yields; neutral; charged; form; stable; paramagnetic; mn; mri; contrast; applications; disclosed; form stable; imaging agents; transition metals; transition metal; stable compound; radiopharmaceutical imaging; imaging agent; contrast agents; contrast agent; therapeutic compounds; multifunctional ligand; diagnostic radiopharmaceutical; /424/999/

Citation Formats

Katti, Kattesh V, Volkert, Wynn A, Ketring, Alan R, and Singh, Prahlad R. New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents. United States: N. p., 1997. Web.
Katti, Kattesh V, Volkert, Wynn A, Ketring, Alan R, & Singh, Prahlad R. New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents. United States.
Katti, Kattesh V, Volkert, Wynn A, Ketring, Alan R, and Singh, Prahlad R. Wed . "New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents". United States. https://www.osti.gov/servlets/purl/870821.
@article{osti_870821,
title = {New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents},
author = {Katti, Kattesh V and Volkert, Wynn A and Ketring, Alan R and Singh, Prahlad R},
abstractNote = {A class of diagnostic and therapeutic compounds derived from phosphinimines that include ligands containing either a single phosphinimine functionality or both a phosphinimine group and a phosphine or arsine group, or an aminato group, or a second phosphinimine moiety. These phosphinimine ligands are complexed to early transition metal radionuclides (e.g. .sup.99m Tc or .sup.186 Re/.sup.188 Re) or late transition metals (e.g., .sup.105 Rh or .sup.109 Pd). The complexes with these metals .sup.186 Re/.sup.188 Re, .sup.99m Tc and .sup.109 Pd exhibit a high in vitro and high in vivo stability. The complexes are formed in high yields and can be neutral or charged. These ligands can also be used to form stable compounds with paramagnetic transition metals (e.g. Fe and Mn) for potential use as MRI contrast agents. Applications for the use of ligands and making the ligands are also disclosed.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Wed Jan 01 00:00:00 EST 1997},
month = {Wed Jan 01 00:00:00 EST 1997}
}

Works referenced in this record:

Radiopharmaceuticals for imaging myocardial perfusion
journal, April 1990


The Radiobiology of Targeted Radiotherapy
journal, January 1990


Advances in contrast-enhanced MR imaging. Principles.
journal, February 1991


Synthesis and in vivo testing of a bromobutyl substituted 1,2-dithia-5,9-diazacycloundecane: a versatile precursor for new 99mTc-bis(aminoethanethiol) complexes
journal, January 1989


Novel bifunctional linkers for antibody chelation with radiometals
book, January 1990


Preparation and structural characterization of salts of oxotetrachlorotechnetate(V)
journal, November 1979


Some triphenylphosphinimine complexes of zinc, cadmium, mercury, rhodium and palladium
journal, January 1979


The Chemistry of Phosphinimines
journal, January 1981


Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent
journal, July 1985


Covalent attachment of chelating groups to macromolecules
journal, July 1977


Pharmacokinetics and clinical application of technetium 99m-labeled hepatobiliary agents
journal, April 1990


2 The clinical use of somatostatin analogues in the treatment of cancer
journal, March 1990


The chemistry of 99mTc-labeled radiopharmaceuticals
journal, January 1990


High oxidation state technetium and rhenium complexes of hydrotris(1-pyrazolyl)borate
journal, December 1991


Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent.
journal, June 1988


Current and future radiopharmaceuticals for brain imaging with single photon emission computed tomography
journal, October 1990


Production and Use of Prospective Radionuclides for Radioimmunotherapy
book, January 1988


Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies
journal, January 1991


Radiolabeled Phosphonic acid Chelates: Potential Therapeutic Agents for Treatment of Skeletal Metastases
journal, January 1989


The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine
journal, January 1986

  • Deutsch, Edward; Libson, Karen; Vanderheyden, Jean-Luc
  • International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, Vol. 13, Issue 4
  • https://doi.org/10.1016/0883-2897(86)90027-9

Chelates and antibodies: Current methods and new directions
book, January 1990


Gd-DPTA: an i.v. contrast agent for clinical MRI
journal, January 1988


Transition Metal Chemistry of a Novel and Versatile Heterodifunctional Phosphorus-Nitrogen Ligand System
journal, May 1990


Technetium-99m spiperone dithiocarbamate: A potential radiopharmaceutical for dopamine receptor imaging with SPECT
journal, January 1989

  • Ballinger, James R.; Gulenchyn, Karen Y.; Hassan, Mohamed N.
  • International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, Vol. 40, Issue 6
  • https://doi.org/10.1016/0883-2889(89)90145-7

Tumour targeting with radiolabelled macrocycle–antibody conjugates
journal, January 1990


Interposition of different chemical linkages between antibody and 111In-DTPA to accelerate clearance from non-target organs and blood
journal, January 1989

  • Paik, Chang H.; Quadri, Syed M.; Reba, Richard C.
  • International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, Vol. 16, Issue 5
  • https://doi.org/10.1016/0883-2897(89)90059-7

Bifunctional chelating agents for radiometal-labeled monoclonal antibodies
book, January 1990